Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of recombinant anti-IL-4Rα humanized monoclonal antibody (611) in Chinese pediatric patients with moderate-to-severe atopic dermatitis
CTR20263101Phase 3Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SSGJ-611 in atopic dermatitis (AD) (4 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Part A: pharmacokinetic parameters of 611, Part B: proportion of participants achieving EASI-75 and 1 more. Started Sep 2026; status: active.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20263101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263101.